Broad receptor tropism and immunogenicity of a clade 3 sarbecovirus
J Lee, SK Zepeda, YJ Park, AL Taylor, J Quispe… - Cell Host & Microbe, 2023 - cell.com
Although Rhinolophus bats harbor diverse clade 3 sarbecoviruses, the structural
determinants of receptor tropism along with the antigenicity of their spike (S) glycoproteins …
determinants of receptor tropism along with the antigenicity of their spike (S) glycoproteins …
Bivalent COVID-19 mRNA booster vaccination (BA. 1 or BA. 4/BA. 5) increases neutralization of matched Omicron variants
DN Springer, M Bauer, I Medits, JV Camp, SW Aberle… - npj Vaccines, 2023 - nature.com
We report SARS-CoV-2 neutralizing antibody titers in sera of triple-vaccinated individuals
who received a booster dose of an original monovalent or a bivalent BA. 1-or BA. 4/BA. 5 …
who received a booster dose of an original monovalent or a bivalent BA. 1-or BA. 4/BA. 5 …
Enhanced neutralization escape to therapeutic monoclonal antibodies by SARS-CoV-2 omicron sub-lineages
The landscape of SARS-CoV-2 variants dramatically diversified with the simultaneous
appearance of multiple subvariants originating from BA. 2, BA. 4, and BA. 5 Omicron sub …
appearance of multiple subvariants originating from BA. 2, BA. 4, and BA. 5 Omicron sub …
High-resolution map of the Fc functions mediated by COVID-19-neutralizing antibodies
I Paciello, G Maccari, E Pantano… - Proceedings of the …, 2024 - National Acad Sciences
A growing body of evidence shows that fragment crystallizable (Fc)-dependent antibody
effector functions play an important role in protection from severe acute respiratory …
effector functions play an important role in protection from severe acute respiratory …
Repeated Omicron infection alleviates SARS-CoV-2 immune imprinting
A Yisimayi, W Song, J Wang, F Jian, Y Yu, X Chen… - Biorxiv, 2023 - biorxiv.org
The continuous emergence of highly immune evasive SARS-CoV-2 variants, like XBB. 1.51,
2 and XBB. 1.163, 4, highlights the need to update COVID-19 vaccine compositions …
2 and XBB. 1.163, 4, highlights the need to update COVID-19 vaccine compositions …
Activity of Sotrovimab against BQ. 1.1 and XBB. 1 Omicron sublineages in a hamster model
JS Driouich, O Bernadin, F Touret, X de Lamballerie… - Antiviral Research, 2023 - Elsevier
The successive emergence of SARS-CoV-2 Omicron variants has completely changed the
modalities of use of therapeutic monoclonal antibodies. Recent in vitro studies indicated that …
modalities of use of therapeutic monoclonal antibodies. Recent in vitro studies indicated that …
Executive summary of the consensus statement of the group for the study of infection in transplantation and other immunocompromised host (GESITRA-IC) of the …
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) arose in December 2019
in China rapidly evolving to the Coronavirus Disease 2019 (COVID-19) pandemic. Since …
in China rapidly evolving to the Coronavirus Disease 2019 (COVID-19) pandemic. Since …
Structural basis for broad neutralization of human antibody against Omicron sublineages and evasion by XBB variant
H Sun, Y Wang, X Chen, Y Jiang, S Wang… - Journal of …, 2023 - Am Soc Microbiol
The continuous emergence of SARS-CoV-2 variants, particularly the newly circulating
Omicron XBB subvariants, has led to a significant reduction in the neutralizing potency and …
Omicron XBB subvariants, has led to a significant reduction in the neutralizing potency and …
[PDF][PDF] Hinweise zu Erkennung, Diagnostik und Therapie von Patienten mit COVID-19
T Feldt, W Guggemos, K Heim, C Lübbert… - Ständiger Arbeitskr der …, 2021 - rki.de
Die SARS-CoV-2-Pandemie stellte unser gesamtes Gesundheitssystem vor große
Herausforderungen. Beispiellos im Zuge der Pandemie wird Evidenz in Studien generiert …
Herausforderungen. Beispiellos im Zuge der Pandemie wird Evidenz in Studien generiert …
Safety, virology, pharmacokinetics, and clinical experience of high-dose intravenous sotrovimab for the treatment of mild to moderate COVID-19: an open-label clinical …
J Moya, M Temech, S Parra, E Juarez… - Open Forum …, 2023 - academic.oup.com
Background Five hundred milligrams of intravenous (IV) sotrovimab has been shown to be
well tolerated and efficacious against pre-Omicron strains in treating patients with mild to …
well tolerated and efficacious against pre-Omicron strains in treating patients with mild to …